Vor Bio to Participate in the Stifel 2024 Healthcare Conference
12 nov. 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
07 nov. 2024 16h05 HE
|
Vor Biopharma
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as...
Kura Oncology Reports Third Quarter 2024 Financial Results
07 nov. 2024 16h05 HE
|
Kura Oncology, Inc.
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in...
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
05 nov. 2024 09h09 HE
|
Kura Oncology, Inc.
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r...
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against The Toronto-Dominion Bank (NYSE: TD); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
29 oct. 2024 18h36 HE
|
DiCello Levitt LLP
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired The Toronto-Dominion Bank (NYSE: TD)...
Lucinity and Facctum Partner for AI-Powered, Real-Time Watchlist Screening and Investigations
08 oct. 2024 07h43 HE
|
Lucinity
Lucinity and Facctum Partner for AI-Powered, Real-Time Watchlist Screening and Investigations
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
30 sept. 2024 07h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...
AB Science fait aujourd'hui le point sur le programme microtubule AB8939 et en particulier sur la capacité d'AB8939 à générer une réponse sur le réarrangement du gène MECOM
26 sept. 2024 02h28 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LE PROGRAMME MICROTUBULE AB8939 ET EN PARTICULIER SUR LA CAPACITÉ D’AB8939 À GÉNÉRER UNE RÉPONSE SUR LE REARRANGEMENT DU GENE MECOM Paris, 26...
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
26 sept. 2024 02h28 HE
|
AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET...
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)